// App-Quantinova.ai

5047 : Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated with abiraterone acetate (AA).

Researchers

Presenter

  • Charles J. Ryan

Principal Investigators

  • Thian Kheoh

  • Jinhui Li

  • Joan Carles

  • Eleni Efstathiou

  • Philip W. Kantoff

  • Peter F.A. Mulders

  • Fred Saad

  • Thomas W. Griffin

  • Kim N. Chi

  • Arturo Molina

  • Peter De Porre

Medical Centers

  • Vall dHebron University Hospital Institute of Oncology, Barcelona, Spain

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Radboud University Nijmegen Medical Centre, Nijmegen, NetherlandsDevelopment, Beerse, BelgiumBC Cancer Agency, Vancouver, BC, Canada

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Janssen Research & Development, Los Angeles, CA

  • Johnson & Johnson Medical China, Shanghai, China

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • Development, Menlo Park, CA

  • University of Montreal, Montreal, QC, Canada

Locations

  • United States

  • Spain

  • China

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved